Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 6 records in total 6
    records per page




    Risk of SARS-CoV2-related Mortality in Non-small Cell Lung Cancer MESHD Patients Treated With First-line Immunotherapy Alone or in Combination With Chemotherapy

    Authors: Giuseppe Luigi Banna; Ornella Cantale; Alex Friedlaender; Harliana Yusof; Alfredo Addeo

    doi:10.21203/rs.3.rs-167896/v1 Date: 2021-01-28 Source: ResearchSquare

    Background: Patients with cancer MESHD are vulnerable to severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), although the impact of solid cancer MESHD types and systemic anticancer treatments on its related mortality is still debatable.Methods: To weigh the real impact of immune-checkpoint inhibitors (ICIs) by exploring the risk of SARS-CoV-2-related mortality in a retrospective analysis of patients with non-small-cell lung cancer MESHD ( NSCLC MESHD) treated with first-line Pembrolizumab or in combination with chemotherapy (ChT) during the first surge of the pandemic. Results: The risk of death was significantly higher in the group of patients treated with ChT+Pembrolizumab than with Pembrolizumab alone (OR 2.43 (1.23-4.82, p=0.01). The SARS-CoV-2-related mortality rate was 8% and significantly associated with ChT+Pembrolizumab as compared to Pembrolizumab alone (18% vs. 0%, respectively, p=0.03). Patients dead because of SARS-CoV-2 were older than 70 years (100 vs. 34%, respectively, p=0.03) and tended to have a heavier smoking history (67 vs. 29% of current smokers, respectively, p=0.17). Higher baseline values of neutrophil-to-lymphocyte ratio (NLR) (with 67 vs. 50% ≥ 4.0, p=0.58) and systemic immune-inflammation index (SII) (with 67 vs. 50% ≥ 1236, p=0.58) were observed in patients dead due to the SARS-CoV-2.Conclusions: Immunotherapy might not impact the risk of SARS-CoV-2-related mortality, whilst the addition of ChT was either associated with an overall increased risk of mortality and to the risk of SARS-CoV-2-related mortality. The co-existence of other clinical factors may have contributed to the latter.

    Challenge of treating cancer amid the COVID-19 MESHD COVID-19 MESHD pandemic: case of skeletal muscle metastasis from primary carcinoma of the lung mistaken as sarcoma

    Authors: Maria Gloria Elisha Casas; Mamer Rosario; Geoffrey Battad; Adrienne Camille Mercado; Trisha Ann Hermogenes; Alvin Hernandez; Janelyn Dy-Ledesma; Avelino Alomesen; Juancho Lorenzo Valera; Arnel Christian Dy

    doi:10.21203/rs.3.rs-88875/v1 Date: 2020-10-06 Source: ResearchSquare

    Background. The authors report on an extremely rare case of skeletal muscle metastasis from primary lung cancer MESHD that involved the radial nerve and humerus, which was “overtreated” with wide tumor MESHD resection and frozen autograft reconstruction upon misdiagnosis of sarcoma MESHD by intraoperative frozen section, amid pressure of expediting hospital care during the COVID-19 MESHD COVID-19 MESHD pandemic.     Case presentation. A 61-year-old male living outside Metro Manila presented with painful mass in his left distal arm during the enhanced community quarantine, and requested admission upon testing negative for COVID-19 MESHD. Imaging studies suggested a diagnosis of soft tissue sarcoma MESHD involving the radial nerve and humerus, and intending to prevent nosocomial SARS-CoV-2 infection MESHD SARS-CoV-2 infection MESHD of patient, treatment was expedited by foregoing biopsy and opting for intraoperative frozen section prior to resection. Frozen section findings suggested malignancy intraoperatively, and we proceeded with wide tumor MESHD resection and frozen autograft reconstruction of the humerus using plates and screws. However, permanent sections revealed metastatic carcinoma MESHD from primary non-small cell lung cancer MESHD, with PET scan confirming lung mass in the right apical lobe.        Conclusion. The report concludes that establishment of a definite tumor MESHD diagnosis by final histopathological analysis is indispensable, even when planning for emergent surgery in the time of COVID-19 pandemic MESHD.

    Collateral effects of the coronavirus disease 2019 MESHD pandemic on lung cancer diagnosis in Korea

    Authors: Ji Young Park; Ye Jin Lee; Taehee Kim; Chang Youl Lee; Hwan Il Kim; Joo-Hee Kim; Sunghoon Park; Yong Il Hwang; Ki-Suck Jung; Seung Hun Jang

    doi:10.21203/rs.3.rs-81855/v1 Date: 2020-09-22 Source: ResearchSquare

    Background The COVID-19 pandemic MESHD COVID-19 pandemic MESHD is predicted to significantly affect patients with lung cancer MESHD, owing to its rapid progression and high mortality. Studies on lung cancer MESHD diagnosis and treatment during an epidemic are lacking. We analyzed the impact of COVID-19 MESHD on lung cancer MESHD diagnosis in Korea, where lung cancer MESHD incidence continues to rise.Methods The number of newly diagnosed lung cancer MESHD cases in three university-affiliated hospitals during the pandemic and their clinical features were compared with lung cancer MESHD cases diagnosed during the same period in the past three years. The effectiveness of measures taken by the study hospitals to prevent nosocomial transmission was reviewed.Results Between February and June during 2017–2020. 612 patients with lung cancer MESHD were diagnosed. During the pandemic, the number of patients who sought consultation at the division of pulmonology of study hospitals dropped by 16% from the previous year. Responding to the pandemic, the involved hospitals created physically isolated triage areas for patients with acute respiratory infection MESHD symptoms. Wide-range screening and preventive measures were implemented, thus minimizing delay in lung cancer MESHD diagnosis. No patients acquired COVID-19 MESHD due to hospital exposure. The proportion of patients with stage III–IV non-small-cell lung cancer MESHD ( NSCLC MESHD) significantly increased (2020: 74.7% vs. 2017: 57.9%, 2018: 66.7%, 2019: 62.7%, p=0.011). The number of lung cancers MESHD diagnosed during this period and the previous year remained the same.Conclusion The proportion of patients with advanced NSCLC MESHD increased during the COVID-19 pandemic MESHD

    Evaluation of non-small cell lung cancer treatment strategies in a region of China with low-risk for COVID-19 MESHD

    Authors: Minhao Yu; Yalin Cheng

    doi:10.21203/rs.3.rs-78352/v2 Date: 2020-09-15 Source: ResearchSquare

    Purpose This study analyzed the morbidity and mortality associated with non-small cell lung cancer MESHD ( NSCLC MESHD) and evaluated treatment strategies for it in a low-risk area of COVID-19 MESHD in China. Materials and methods: We selected patients admitted to Sichuan Science City Hospital from September 2019 to February 2020 and divided them into experimental and control groups. The treatment strategy was evaluated by patients’ prognosis. Results: 9,010 patients were hospitalized. The total morbidity was 0.699%, of which 0.504% was observed in the control group and 0.991% in the experimental group (P=0.024). The total mortality was 0.999/103, of which 0.630/103 was observed in the control group and 1.413/103 in the experimental group (P=0.322). Therapy discontinuation and cancer MESHD progression in the experimental group were significantly higher than the control group (P<0.001, P=0.007). The treatment methods and prognosis were not significantly different for early-stage patients between the two groups. Late-stage patients in the experimental group experienced significantly lower percentages of non-surgical treatments (P<0.001), higher percentages of discontinued therapies (P<0.001), lower percentages for prognosis of wellness (P<0.001), and higher percentages of cancer MESHD progression (P<0.001) than the control group. Conclusion: NSCLC MESHD exhibited significantly higher morbidities during the COVID-19 pandemic MESHD. The mortality in the experimental group was slightly higher than the control group, while the difference in cancer MESHD progression was significant. It is feasible to perform surgery for early-stage NSCLC MESHD patients, and treatment should not be suspended for late-stage patients in regions with low-risk for COVID-19 MESHD infection.

    A false alarm of COVID-19 MESHD pneumonia in lung cancer: a case report of anti-PD-1 related pneumonitis and literature review

    Authors: Ying Dai; Ying Dai; Sha Liu; Sha Liu; Zhiyan Zhao; Zhiyan Zhao; Xiaqiu Li; Xiaqiu Li; Yiruo Zhang; Yiruo Zhang; Pingping Liu; Pingping Liu; Yingying Du; Yingying Du

    doi:10.21203/rs.3.rs-41095/v1 Date: 2020-07-11 Source: ResearchSquare

    Background: The fatal toxicity MESHD of anti-PD-1/ PD-L1 HGNC agents is pneumonitis MESHD. The diagnosis consists of the history of immunotherapy, clinical symptoms and presentation of computed tomography (CT) imaging. The typical CT findings include ground-glass opacities. Based on the similar radiographic feature with 2019 Novel Coronavirus ( COVID-19 MESHD) pneumonia MESHD, clinicians are cautious to evaluate diagnosis especially in COVID-19 MESHD epidemic areas. Case presentation: Herein we report a 67-year-old male patient with advanced non-small cell lung cancer MESHD developed pneumonitis MESHD post Sintilimab injection. The dyspnea MESHD appeared at the 15th day of close contact with his son who returned from Wuhan, but not accompanied with fever MESHD. The chest CT indicated peripherally subpleural lattice opacities at the inferior right lung lobe and bilateral thoracic infusion. The real-time reverse-transcription polymerase-chain-reaction (RT-PCR) from double swab samples within 72 hours remained negative. The patient was thereafter treated with prednisolone and antibiotics for over two weeks. Thereafter the chest CT demonstrated the former lesion almost absorbed, in line with prominently falling CRP HGNC level. The anti-PD-1 related pneumonitis MESHD with bacterial infection MESHD was diagnosed finally based on the clinical evidence and good response to the prednisolone and antibiotics. Conclusion: Both ani-PD-1 related pneumonitis MESHD and COVID-19 MESHD pneumonia harbor the common clinical symptom and the varied features of CT imaging. Differential diagnosis was based on the epidemiological and immunotherapy histories, RT-PCR tests. The response to glucocorticoid can indirectly help the diagnosis.

    Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 MESHD Global Pandemic

    Authors: Sameera Kumar; Steven Chmura; Clifford Robinson; Steven H. Lin; Shirish M. Gadgeel; Jessica Donington; Josephine Feliciano; Thomas E. Stinchcombe; Maria Werner-Wasik; Martin J. Edelman; Drew Moghanaki

    id:10.20944/preprints202004.0236.v1 Date: 2020-04-15 Source: Preprints.org

    Importance: The COVID-19 pandemic MESHD COVID-19 pandemic MESHD is currently accelerating. Patients with locally advanced non-small cell lung cancer MESHD ( LA-NSCLC MESHD) may require treatment in locations where resources are limited and the prevalence of infection is high. Patients with LA-NSCLC MESHD frequently present with comorbidities that increase the risk for severe morbidity and mortality from COVID-19 MESHD. These risks may be further increased by treatments for LA-NSCLC MESHD. Observation: We present expert thoracic oncology multidisciplinary (radiation oncology, medical oncology, surgical oncology) consensus of alternative strategies for the treatment of LA-NSCLC MESHD during a pandemic. The overarching goals of these approaches are to reduce the number of visits to a healthcare facility, reduce the risk of SARS-CoV-2 exposure, and attenuate the immunocompromising effects of lung cancer MESHD therapies. Patients with resectable disease can be treated with definitive non-operative management if surgical resources are limited or the risks of perioperative care are high. Non-operative options include chemotherapy, chemoimmunotherapy, and radiation therapy with sequential schedules. The order of treatments may be based on patient factors and clinical resources. Whenever radiation therapy is delivered without concurrent chemotherapy, hypofractionated schedules are appropriate. For patients who are confirmed to have COVID-19 MESHD, usually cancer MESHD therapies may be withheld until symptoms have resolved with negative viral test results. Conclusions and Relevance: The risk of severe treatment-related morbidity and mortality is significantly elevated for patients undergoing treatment for LA-NSCLC MESHD during the COVID-19 pandemic MESHD. Adapting alternative treatment strategies as quickly as possible may save lives and should be implemented through communication with the multidisciplinary cancer MESHD team.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.